Plasma YKL-40 is elevated in some patients with acute myeloid leukemia [99], multiple myeloma [96,100,101], and Hodgkin lymphoma [102], and high pre-treatment plasma YKL-40 is associated with short survival [96,99,100]. This evidence concerns the gene CHI3L1 and plasma cell myeloma.